The 7 major patau syndrome markets reached a value of USD 502.0 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,062.3 Million by 2035, exhibiting a growth rate (CAGR) of 7.06% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 502.0 Million |
Market Forecast in 2035
|
USD 1,062.3 Million |
Market Growth Rate (2025-2035)
|
7.06% |
The patau syndrome market has been comprehensively analyzed in IMARC's new report titled "Patau Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Patau syndrome is a less common genetic condition brought about by trisomy 13. The condition occurs as a result of an additional copy of chromosome 13, resulting in critical developmental abnormalities, such as congenital heart abnormalities, brain defects, cleft lip/palate, polydactyly, and numerous organ malformations. Infants affected by the condition usually have extreme intellectual disabilities and significantly shortened life spans, with most cases ending in death in the first year of life because of extreme complications. The diagnosis of Patau syndrome is mainly by prenatal screening, e.g., non-invasive prenatal testing (NIPT), maternal serum screening, or ultrasound scanning, to identify structural defects. Confirmation is done by karyotyping or fluorescence in situ hybridization (FISH) to detect chromosomal defects. Diagnosis after birth is based on clinical assessment and genetic testing. Because of the severity of the symptoms, treatment is supportive and palliative, aimed at symptom management, surgical procedures for congenital abnormalities, and multidisciplinary interventions to improve the quality of life in affected infants.
The increasing rate of advanced maternal age pregnancies, which is an established risk factor for chromosomal disorders, is one of the main drivers in the Patau syndrome market. As women become older, there are increasing occurrences of trisomy 13, promoting more demand for early diagnosis and screening technologies. In addition to this, rapid growth in genetic testing like NGS and enhanced carrier screening has facilitated enhanced rates of early detection, thus enhancing prenatal decision-making. The growing use of non-invasive prenatal testing (NIPT) is also driving market growth by offering precise and early diagnoses with little risk to the fetus. Additionally, advancements in fetal surgery methods provide potential treatments for congenital defects, although their use is still limited because of the severity of the condition. Advances in pediatric palliative care and neonatal intensive care services are improving the quality of life for affected babies, fueling market growth. Increasing awareness of genetic counseling services is also increasing demand, as medical professionals prioritize informed decision-making for parents. Furthermore, new research into gene therapy and targeted interventions may unlock new possibilities in the market, even with current treatment constraints.
IMARC Group's new report provides an exhaustive analysis of the patau syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the patau syndrome market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current patau syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Market Insights
Epidemiology Insights
Patau Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies